Omega Healthcare Investors Inc "Highlights From Meetings With Management" (Buy)

Research evidence excerpt

Omega Healthcare Investors Inc "Highlights From Meetings With Management" (Buy)

for the larger REITs such as WELL and VTR. Further, given OHI's background in

higher acuity SNFs, it has not stayed away from higher acuity SHOP deals in

assisted living and memory care. OHI spends a lot of time making sure it is buying

in the right micromarket. Additionally, Omega has invested in its RIDEA capabilities

by bring in key hires in the SHOP industry with strong rolodexes. On UK care

homes, the fragmented nature of the market continues to provide the most

consistent source of deal flow. This should eventually lead to the company's first

UK RIDEA transaction in the near future. On SNFs, it indicated there isn't a lot of

SNF portfolios coming to market, which likely reflects many SNF owners

and operators having already exited in the past ten years. While looking to partake

in SNF deals going forward, volumes in 2026 and beyond may not look the same

as in years past. We think this is evidenced by its pipeline.

Funding path for transactions in place. Given the expected transaction

volume, there is strong visibility around OHI's funding options. Notably, OHI should

be able to reinvest the future proceeds from the 2Q'26 Communicare sales of

$480 mm, as well as loan & mortgage repayments of $318 mm ($160 mm of

Genesis at 14%). Additionally, OHI may use equity for incremental purchases.

Though, it remains hesitant to issue equity in size given some of its recent

initiatives that it expects to help its share price. OHI would likely issue equity to

repay any expiring debt. It would consider long-term HUD debt if pricing gets

more attractive. Its balance sheet is in a good place. Its net-debt-to-EBITDA is

currently 3.5x, and the closing of the Communicare sales in 2Q'26 would take that